Novavax plots to reduce European footprint to become a ‘leaner’ company

No­vavax is “ac­tive­ly ex­plor­ing” to di­vest its man­u­fac­tur­ing fa­cil­i­ty in the Czech Re­pub­lic as the com­pa­ny con­tin­ues to face dwin­dling de­mand for its vac­cines, CFO …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Year in Review: Tardive Dyskinesia

In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights

Read More »